I read with great interest the article by Truog et al. 1 in which they report on the clinical predictors and financial implications of the availability of inhaled nitric oxide (INO) for the treatment of neonatal pulmonary hypertension in term and near-term infants. They report that use of INO resulted in net financial ''savings'' of $10,170 per patient (i.e. $895,000 for 88 reported neonates). I, however, feel that there is flaw in the methodology adopted by the authors in the calculation of the ''savings'' resulting from the use of INO.
Truog et al. present the analysis for 88 infants who met the inclusion criteria between March 1994 and March 2000. The charges generated in the treatment included total INO charges for all 88 infants of $1,048,000 and total ECMO charges of $1,710,000 for 36 (41%) neonates. Thus, the total charges for the treatment of these neonates in the study under discussion add up to $2,758,000.
For calculating ''savings'', the authors have made comparisons with two hypothetical situations. In the first hypothetical scenario, it is assumed that in the absence of INO, all 88 patients would have been treated with ECMO, generating charges of $4,020,000 (assuming a current cumulative charge for a 6-day uncomplicated ECMO course of $45,700). In this case, as appropriately shown by the authors, the savings would be the difference between the charges generated if all 88 neonates were treated with ECMO and the actual charges incurred as reported in the study, that is, ($4,020,000À$2,758,000) ¼ $1,262,000 or $14,300 per patient.
In the second hypothetical scenario, the authors applied the ECMO usage rate of 65% as previously reported for the control groups in trials using INO. [2] [3] [4] [5] [6] This generated a charge of $2,605,000 (approx. $45,700 Â 88 Â 0.65) against the actual incurred charge of $2,758,000 reported in their study for 88 patients. Hence the saving should be calculated as Thus, the data presented suggest that the use of INO in the study was associated with a net ''increase in charges'' of $153,000 or B1738 per patient if an ECMO usage rate of 65% was used, in contrast to ''savings'' incorrectly claimed by the authors. A net increase in charges with the use of INO was also reported by Jacobs et al. 7 
